Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial

被引：0

作者：

Strasser, S. ^{[1
,2
]}

Abou-Alfa, G. ^{[8
]}

Mollon, P. ^{[3
]}

Meyer, T. ^{[5
]}

Cheng, A. ^{[6
,7
]}

El-Khoueiry, A. ^{[9
]}

Kelley, R. ^{[10
]}

Baron, A. ^{[11
]}

Benzaghou, F. ^{[4
]}

Valcheva, V. ^{[3
]}

Hazra, S. ^{[12
]}

Mangeshkar, M. ^{[12
]}

Freemantle, N. ^{[5
]}

机构：

[1] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[2] Univ Sydney, Sydney, NSW, Australia

[3] Ipsen Pharma SAS, Boulogne, France

[4] Ipsen Innovat, Les Ulis, France

[5] UCL, London, England

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[10] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[11] Calif Pacific Med Ctr, San Francisco, CA USA

[12] Exelixis Inc, San Francisco, CA USA

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

444

引用

页码：43 / 43

页数：1

共 50 条

[1] Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
Trojan, J.
Abou-Alfa, G. K.
Mollon, P.
Meyer, T.
Cheng, A. -L.
El-Khoueiry, A. B.
Kelley, R. K.
Baron, A. D.
Benzaghou, F.
Valcheva, V.
Hazra, S.
Mangeshkar, M.
Freemantle, N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 241 - 241
[2] Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial
Venerito, Marino
Abou-Alfa, G. K.
Mollon, P.
Meyer, T.
Cheng, A. -L
El-Khoueiry, A. B.
Kelley, R. K.
Baron, A. D.
Benzaghou, F.
Valcheva, V.
Hazra, S.
Mangeshkar, M.
Freemantle, N.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 61 - 61
[3] Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
Abou-Alfa, Ghassan K.
Mollon, Patrick
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Kelley, Robin Kate
Baron, Ari David
Benzaghou, Fawzi
Valcheva, Velichka Valerieva
Hazra, Saswati
Mangeshkar, Milan
Freemantle, Nicholas
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[4] Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
Freemantle, Nick
Mollon, Patrick
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Kelley, Robin K.
Baron, Ari D.
Benzaghou, Fawzi
Mangeshkar, Milan
Abou-Alfa, Ghassan K.
EUROPEAN JOURNAL OF CANCER, 2022, 168 : 91 - 98
[5] QUALITY-ADJUSTED LIFE-YEARS
WILLIAMS, A
LANCET, 1987, 1 (8546): : 1372 - 1372
[6] QUALITY-ADJUSTED LIFE-YEARS
SMITH, A
LANCET, 1987, 2 (8549): : 47 - 47
[7] The visibility and divisibility of quality-adjusted life-years
Mullins, CD
CLINICAL THERAPEUTICS, 2005, 27 (08) : 1276 - 1277
[8] Income-related inequality in life-years and quality-adjusted life-years
Gerdtham, UG
Johannesson, M
JOURNAL OF HEALTH ECONOMICS, 2000, 19 (06) : 1007 - 1026
[9] The quality-adjusted life-years in the oncological patients’ health-related quality of life
Karolina Kucnerowicz
Agata Pietrzak
Witold Cholewiński
Piotr Martenka
Andrzej Marszałek
Ewa Burchardt
Erwin Strzesak
Scientific Reports, 12
[10] Quality-Adjusted Life-Years without Constant Proportionality
Craig, Benjamin M.
Rand, Kim
Bailey, Henry
Stalmeier, Peep F. M.
VALUE IN HEALTH, 2018, 21 (09) : 1124 - 1131

← 1 2 3 4 5 →